|
|
Recombinant Human Interferon α2b Vaginal Effervescent Capsules in the treatment of patients with HPV infection: a Meta-analysis |
ZHANG Shudan1 LI Qi2 LI Ge3 |
1.Department of Pharmacy, Dalian Hospital of Traditional Chinese Medicine, Liaoning Province, Dalian 116013, China;
2.Department of Internal Medicine, the Third Hospital of Wafangdian, Liaoning Province, Wafangdian 116300, China;
3.Department of Oncology, Dalian Hospital of Traditional Chinese Medicine, Liaoning Province, Dalian 116013, China |
|
|
Abstract Objective To review systematically the curative effect and safety of Recombinant Human Interferon α2b Vaginal Effervescent Capsules (Xinfuning) on HPV infection, and provide clinicians with an evidence base for their clinical decision making. Methods The databases of PubMed, EMbase, Cochrane Library, CBM, Wanfang, CNKI and VIP were retrieved for collecting RCT and CCT about the treatment of HPV infection with Xinfuning before May 2017, and reference lists were also searched. According to the inclusion and exclusion criteria, two reviewers screened and assessed the potential studies independently, and then the data was extracted. The data was given a Meta-analysis by using RevMan 5.3 software. Results Twenty-three study articles were included, involving 3442 patients. After 3 months, the test results showed that the clinical curative effect of Xinfuning treatment group in treating human papilloma virus was better than that of control group (OR = 11.67, 95%CI: 5.50-24.75, P < 0.000 01). After 6 months, the test results showed that the clinical curative effect of Xinfuning treatment group in treating human papilloma virus was better than that of control group (OR = 2.03, 95%CI: 1.41-2.92, P = 0.0001). After 12 months, the test results showed no significant differences of clinical curative effect between Xinfuning treatment group and the control group (OR = 1.24, 95%CI: 0.85-1.81, P = 0.26). There were no obvious adverse reactions in the two groups. Conclusion Xinfuning has significant curative effect in treating HPV infection, and the safety is good.
|
|
|
|
|
[1] Tsiodras S,Georgoulakis J,Chranioti A,et al. Hybrid capture vs. PCR screening of cervical human papilloma virus infections. Cytological and histological associations in 1270 women [J]. BMC Cancer,2010,10(1):1-8.
[2] 李爱禄,贺锦曦,饶靖红,等.重组人干扰素α2b阴道泡腾胶囊治疗宫颈HPV感染64例临床分析[J].实用妇产科杂志,2010,26(5):395-396.
[3] 宋志琴,孙丽丽,王蔼明.重组人干扰素α-2b阴道泡腾胶囊治疗宫颈高危型HPV感染疗效分析[J].现代妇产科进展,2011,20(5):412-413.
[4] 鲁淑英,马英英.重组人干扰素α-2b阴道泡腾胶囊治疗生殖道HPV感染的临床观察[J].海峡药学,2011,23(12):118-119.
[5] 周桂月.重组人干扰素α-2b阴道泡腾胶囊治疗宫颈HPV感染临床分析[J].江苏卫生保健,2011,13(6):45,53.
[6] 姚玉君.重组人干扰素α2b阴道泡腾胶囊治疗宫颈HPV感染疗效观察[J].中国伤残医学,2012,20(6):86-87.
[7] 张喜红.重组人干扰素α-2b阴道泡腾胶囊治疗宫颈低度上皮内瘤变疗效观察[J].中国社区医师:医学专业,2012,14(15):79.
[8] 陈小丽,巴静,黄凤英,等.重组人干扰素α2b阴道泡腾胶囊治疗宫颈HPV感染的临床效果及安全性观察[J].中国医药指南,2014,12(34):19-20.
[9] 胡爱勤,王金华.重组人干扰素α2b阴道泡腾胶囊治疗宫颈人乳头瘤病毒感染的临床研究[J].中国临床药理学杂志,2015,31(4):259-260,263.
[10] 牛凤萍.重组人工干扰素α2b阴道泡腾胶囊(辛复宁)对HPV感染的疗效观察[J].中国医药指南,2015,13(22):159.
[11] 陈晓静,叶菁.阴道局部干扰素应用对宫颈高危型人乳头瘤病毒感染进程影响的临床研究[J].实用妇产科杂志,2016,32(6):450-452.
[12] 郝云涛,郑小影,张玉娟,等.宫颈上皮内瘤变LEEP术后阴道局部用药疗效分析[J].中国妇幼保健,2016,31(17):3508-3510.
[13] 韩淑琴,刘俊霞,耿英桥,等.重组人干扰素α-2b阴道泡腾胶囊联合LEEP术治疗宫颈高危HPV感染的临床观察[J].河北医药,2014,36(10):1511-1512.
[14] 沈姚琴,王华,邓娟.自拟除湿解毒汤联合重组人干扰素α-2b阴道泡腾胶囊治疗宫颈高危型HPV感染的疗效观察[J].中国现代应用药学,2014,31(5):603-606.
[15] 张仕田,杨琴,赵红利.LEEP术在宫颈病变中诊断及其术后联合不同药物治疗的应用[J].慢性病学杂志,2016, 17(1):14-16,20.
[16] 袁涛,李晓.213例宫颈上皮内瘤变Ⅰ期临床疗效观察分析[J].中国伤残医学,2014,22(2):107-108.
[17] 覃烨,谢莉.重组人干扰素α-2b阴道泡腾胶囊联合LEEP治疗宫颈上皮内瘤变的疗效分析[J].武汉大学学报:医学版,2009,30(1):127-129.
[18] 武丽蕊,李红霞,魏玲.微波联合干扰素治疗慢性宫颈炎伴高危型人乳头瘤病毒感染的临床观察[J].医学动物防制,2016,32(12):1364-1366.
[19] 梅泉,杨慧.重组人干扰素α-2b阴道泡腾胶囊在宫颈环形电切术后的应用[J].上海医药,2015,36(10):20-22,28.
[20] 肖鸣盛,谌小英,况业妹.重组人干扰素-α2b阴道泡腾胶囊对宫颈癌伴人乳头瘤病毒感染患者抗病毒治疗的临床疗效评价[J].抗感染药学,2017,14(1):219-220.
[21] 钟汉威,凌勇,赵坚.辛复宁在女性生殖道HPV感染中的治疗作用[J].海峡药学,2012,24(4):226-227.
[22] 孙琰,钱芳波.宫颈环形电切术联合干扰素α2b阴道泡腾胶囊治疗女性尖锐湿疣的临床研究[J].中国性科学,2015,24(11):74-77.
[23] 王炜俊,高燕.辛复宁配合LEEP治疗宫颈上皮内瘤变临床观察[J].现代妇产科进展,2011,20(5):414.
[24] 陈小婷.重组人干扰素α2b阴道泡腾胶囊联合微波治疗慢性宫颈炎伴人乳头瘤病毒感染[J].上海预防医学,2015, 27(1):51-52.
[25] Pretet JL,Jacquard AC,Carcopino X,et al. Human papil?鄄lomavirus(HPV)genotype distribution in invasive cervical cancers in France:EDITH study [J]. Int J Cancer,2008, 122(2):428-432. |
|
|
|